NCT03361852View on ClinicalTrials.gov

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 26, 2033

Conditions
Follicular Lymphoma
Interventions
DRUG

Rituximab

Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells

BIOLOGICAL

Neo Vax

"Neo Vax is an experimental viral mimic and an activator of immunity."

DRUG

Pembrolizumab

Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER